Karthik Sarma, founder of SRS Investment Management, is the hedge fund manager who turned a concentrated activist position in Avis Budget Group into one of the most spectacular investment wins of the past decade. After founding SRS in 2006, the former Tiger Cub built a reputation for deep, research-driven conviction, long time horizons, and strategic influence behind the scenes. His most famous trade—SRS’s stake in Avis—generated multibillion-dollar gains as the company’s market value surged, making Sarma one of the top-earning hedge fund managers in America. Known for his low profile, analytical intensity, and disciplined patience, he has become a defining figure in modern activist investing.

John Oyler, cofounder and chairman of BeiGene, is one of the most prominent figures in global oncology drug development, helping build a multinational biopharmaceutical company centered on innovative, accessible cancer therapies. After successful ventures in medical technology and data analytics, he launched BeiGene in 2010 with a mission to integrate world-class research with large-scale clinical operations across Asia, Europe, and the United States. Under his leadership, the company has developed breakthrough cancer drugs, secured major partnerships with industry leaders like Novartis and Amgen, and scaled into a global enterprise listed on multiple exchanges. Known for his scientist–entrepreneur mindset, Oyler has reshaped how biotech innovation and commercialization connect across continents.

Anthony Pratt is the Australian‑born billionaire and executive chairman of Visy Industries and Pratt Industries USA—collectively the world’s largest privately owned paper, packaging, and recycling firm. Under his leadership, the company has expanded to over 70 U.S. factories and pledged a $5 billion investment to create 5,000 American manufacturing jobs, aligning business growth with sustainability and global impact.